3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Active not recruiting
2
Withdrawn
1
Unknown
1
Terminated
1
No longer available
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
11
Gastrointestinal
4
CNS
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Conditions
Brain Neoplasms
2
Breast Neoplasms
1
Interventions
Temozolomide
59
Radiotherapy
37
Magnetic Resonance Spectroscopy
32
Radiosurgery
27
Specimen Handling
23
Cyclophosphamide
21
pembrolizumab
20
Nivolumab
20
Radiation
17
Carboplatin
12
Biopsy
12
Bevacizumab
11
Vincristine
10
Ipilimumab
10
Cisplatin
10
X-Rays
9
Lomustine
8
Irinotecan
8
Immunoglobulin G
8
Etoposide
8
trametinib
7
Disulfides
7
AZD 6244
7
pertuzumab
6
atezolizumab
6
abemaciclib
6
Topotecan
6
Proton Therapy
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
tucatinib
×
CNS
×
Clear all
NCT05323955
2026-03-17
BRIDGET
Duke University
Phase 2
Active not recruiting
48 enrolled
NCT04538742
2025-12-08
DB-07
AstraZeneca
Phase 1/2
Active not recruiting
245 enrolled